Translate the text from English to Welsh.



 
Following yesterday’s announcement of a UK wide trial investigating the benefits of the antiviral medicine molnupiravir in people at risk from COVID\-19, I would like to update members on access to medicines for the treatment of COVID\-19 for patients in Wales.


The PANORAMIC study (Platform adaptive trial of novel antivirals for early treatment of COVID\-19 in the community) is the first clinical trial of its kind. The trial is being led by Oxford University and delivered in Wales by Public Health Wales, Health and Care Research Wales and Cardiff University.


People in Wales will be eligible to take part in the UK\-wide study if they are over 50, or aged between 18 and 49 and have an underlying health condition, if they test positive for COVID\-19 and if they’ve had symptoms for fewer than 5 days. Arrangements are in place for Health and Care Research Wales to contact people in the eligible groups if they test positive for COVID\-19 and to invite them to participate in the PANORAMIC study. Further information about the trial is can be found at the PANORAMIC study website.


Since the early part of last year, a range of therapeutic interventions have been studied as potential treatments for COVID\-19 and some have been shown to improve outcomes. A number of treatments have been shown to be effective in preventing deterioration of patients hospitalised with COVID\-19 and now represent the standard of care in every hospital in Wales.


As the number of effective treatments for hospitalised patients has increased, attention has turned to identifying and treating people at the highest risk earlier in order to prevent hospitalisation. As such alongside the PANORAMIC study, we are also making arrangements to ensure those at the very highest risk from COVID\-19 can access earlier treatment.


This will mean from next week the NHS will begin making the neutralising monoclonal antibody combination casirivimab and imdevimab, marketed in the UK under the brand name Ronapreve, and the antiviral molnupiravir, available within five days of symptom onset and a positive PCR test, where people are at the highest risk of COVID\-19\. This will include amongst others, people who have solid tumour or haematological cancers, who receive treatments that suppress their immune system, who have HIV, and those with some genetic and rare neurological conditions.


People in the eligible treatment groups will shortly begin receiving letters advising what they should do if they have symptoms and test positive for COVID\-19\. More information about COVID\-19 treatments is available at COVID\-19 treatments.







Translation:


 
Yn dilyn y cyhoeddiad ddoe bod treial yn cael ei gynnal ar draws y DU i edrych ar fanteision y feddyginiaeth gwrthfeirol molnwpirafir mewn pobl sy’n wynebu risg yn sgil COVID\-19, hoffwn roi’r wybodaeth ddiweddaraf i Aelodau ar fynediad at feddyginiaethau ar gyfer triniaeth COVID\-19 i gleifion yng Nghymru.


Yr astudiaeth PANORAMIC (Treial llwyfan addasol o feddyginiaethau gwrthfeirol ar gyfer trin COVID\-19 yn gynnar yn y gymuned) yw’r treial clinigol cyntaf o’i fath. Caiff ei arwain gan Brifysgol Rhydychen a’i ddarparu yng Nghymru gan Iechyd Cyhoeddus Cymru, Ymchwil Iechyd a Gofal Cymru a Phrifysgol Caerdydd.


Bydd pobl yng Nghymru yn gymwys i gymryd rhan yn yr astudiaeth ar gyfer y DU gyfan os ydynt dros 50 oed, neu rhwng 18 a 49 oed a bod ganddynt gyflwr iechyd isorweddol, os ydynt wedi cael canlyniad positif i brawf COVID\-19 ac os ydynt wedi cael y symptomau am lai na 5 diwrnod. Mae trefniadau yn eu lle er mwyn i Ymchwil Iechyd a Gofal Cymru gysylltu â phobl yn y grwpiau cymwys os ydynt wedi profi’n bositif ar gyfer COVID\-19 a’u gwahodd i fod yn rhan o’r astudiaeth PANORAMIC. Gallwch weld rhagor o wybodaeth am y treial ar wefan yr astudiaeth PANORAMIC.


Ers yn gynnar y llynedd, mae amrywiaeth o ymyriadau therapiwtig wedi cael eu hastudio fel triniaethau posibl ar gyfer COVID\-19 ac mae rhai wedi dangos eu bod yn gwella canlyniadau. Mae nifer o driniaethau wedi dangos eu bod yn effeithiol wrth atal cleifion sydd wedi’u derbyn i’r ysbyty gyda COVID\-19 rhag dirywio, ac mae’r triniaethau hyn nawr yn rhan o’r gofal safonol ym mhob ysbyty yng Nghymru.


Gan fod y nifer o driniaethau effeithiol ar gyfer cleifion sy’n yr ysbyty wedi cynyddu, mae’r sylw bellach wedi troi at nodi a thrin pobl sydd â’r risg uchaf yn gynt er mwyn eu hatal rhag gorfod mynd i’r ysbyty. Felly, ochr yn ochr â’r astudiaeth PANORAMIC, rydym hefyd yn gwneud trefniadau i sicrhau bod y rheini sy’n wynebu’r risg uchaf bosibl yn sgil COVID\-19 yn cael mynediad at driniaeth yn gynt.


Mae hyn yn golygu, o’r wythnos nesaf ymlaen, y bydd y GIG yn sicrhau bod y cyfuniad o wrthgyrff monoclonaidd a all niwtraleiddio’r feirws, casirifimab ac imdefimab, a gaiff eu marchnata yn y DU dan y brand Ronapreve, a’r feddyginiaeth gwrthfeirol molnwpirafir, ar gael o fewn 5 niwrnod i pan fydd pobl yn dechrau datblygu symptomau neu pan cânt brawf PCR positif, yn achos y bobl hynny sy’n wynebu’r risg uchaf yn sgil COVID\-19\. Ymhlith eraill, bydd hyn yn cynnwys pobl sydd â chanser â thiwmor solet neu ganser haematolegol, sy’n derbyn triniaethau sy’n gwanhau eu system imiwnedd, pobl sydd â HIV, a’r rheini sydd â rhai cyflyrau niwrolegol genetig a phrin.


Bydd pobl yn y grwpiau triniaethau cymwys hefyd yn dechrau cael llythyron yn dweud wrthynt beth ddylent wneud os oes ganddynt symptomau ac os ydynt yn profi’n bositif ar gyfer COVID\-19\. Mae rhagor o wybodaeth am driniaethau COVID\-19 ar gael yn Triniaethau COVID\-19.